GenPhar, Inc. is a biopharmaceutical company dedicated to providing vaccines that protect against infectious diseases with great socio-economic impacts worldwide.
safe and effective
GenPhar's complex and adaptive proprietary technology is designed to develop prophylactic and therapeutic vaccines that protect against multiple virus subtypes in a single construct.
Successful, safe vaccination is the most effective way to prevent infectious diseases. GenPhar's vaccines have consistently proven 100% safe and effective against the strictest of tests and standards.
GenPhar has single and multivalent vaccines for viral diseases including cell-based seasonal and pandemic flu, hepatitis B, hepatitis C, and HIV. Through industry collaborations, these vaccines will become available to improve and save countless lives.
GenPhar is committed to providing vaccine products to combat the world's most dangerous viral diseases.
Biological weapons are easy to produce, indiscriminately lethal, difficult to detect, and highly infectious. Biological attacks are not only capable of destroying an entire army, but also spreading beyond the battlefields and threatening the lives of innocent people.
GenPhar began its biodefense program in 2000 as one of the first in the industry. GenPhar's vaccine platform is ideally designed for biodefense because one vaccine can prevent infection from multiple virus subtypes.
GenPhar has vaccines for lethal viruses such as Ebola, Marburg, dengue and influenza, with several approaching the final stages prior to approval. The company works closely with the DoD in late stage testing prior to conducting clinical studies.
Genphar continues to make impressive progress with it's vaccine platform. See for yourself in our latest vaccine pipeline animations.
Note: requires Adobe Flash viewer plug-in